Fibroblast Activation Protein Inhibitor PET Imaging in Head and Neck Cancer

Röhrich, Manuel

doi:10.1016/j.cpet.2023.02.002

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The eleven studies meeting the criteria for inclusion in the systematic review (qualitative analysis), which included 292 HNC patients, are thoroughly analyzed in Tables 1-3 [11][12][13][14][15][16][17][18][19][20][21]. The selected studies were published from 2020 to 2023 in China (5/11), Germany (5/11), and Thailand (1/11).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…In this regard, FAP inhibitors (FAPi) have been utilized to develop radiopharmaceuticals that can enhance the in vivo expression of FAP through PET imaging, such as [ 68 Ga]Ga-FAPi-02 and [ 68 Ga]Ga-FAPi-04 [10]. In this setting, various studies have employed PET imaging techniques with radiolabeled FAPi to identify HNC lesions in diverse clinical scenarios [11]. This systematic review and meta-analysis aims to perform a comprehensive evaluation to ascertain the diagnostic performance of FAP-targeting radiopharmaceuticals in detecting HNC lesions in different clinical settings, excluding thyroid cancers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Accuracy of [68Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis

Rizzo,

Miceli,

Racca

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Several studies have examined the use of positron emission tomography (PET) using [68Ga]Ga-radiolabeled fibroblast-activation protein inhibitors (FAPi) across multiple subtypes of head and neck cancer (HNC). The purpose of the present study was to evaluate the diagnostic accuracy of a newly developed molecular imaging approach in the context of HNC through a comprehensive review and meta-analysis. A thorough literature review was conducted to identify scholarly articles about the diagnostic effectiveness of FAP-targeted PET imaging. The present study incorporates original publications assessing the efficacy of this innovative molecular imaging test in both newly diagnosed and previously treated HNC patients. This systematic review examined eleven investigations, of which nine were deemed suitable for inclusion in the subsequent meta-analysis. The quantitative synthesis yielded a pooled detection rate of 99% for primary HNC lesions. Additionally, on a per patient-based analysis, the pooled sensitivity and specificity for regional lymph node metastases were found to be 90% and 84%, respectively. The analysis revealed a statistical heterogeneity among the studies for the detection rate of primary HNC lesions. The quantitative findings presented in this study indicate a favorable diagnostic performance of FAP-targeted PET imaging in detecting primary HNC tumors. In contrast, discordant results concerning the diagnostic accuracy of lymph node metastases were found. However, further multicentric trials are required to validate the efficacy of FAP-targeted PET in this specific group of patients.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic Accuracy of [68Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis

Rizzo,

Miceli,

Racca

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

Dual-Time Point 68Ga-FAPI-04 PET/CT Improves Tumor Delineation and Cervical Lymph Node Metastasis Identification in Patients With Head and Neck Squamous Cell Carcinoma

Jiang,

Huang,

Tian

et al. 2024

Clin Nucl Med

View full text Add to dashboard Cite

Purpose The purpose of this study was to evaluate the benefit of dual-time point 68Ga-FAPI-04 PET/CT in staging head and neck squamous cell carcinoma (HNSCC). Patients and Methods Sixty-nine treatment-naive patients with HNSCC were enrolled. Each patient underwent whole-body 68Ga-FAPI-04 PET/CT at approximately 30 minutes postinjection and a delayed scan in head and neck region at 2 hours. Radiotracer uptake (SUVmax), tumor-to-background ratio, change in SUVmax (∆SUVmax), retention index, diagnostic performance, and staging were explored. Histopathology was the reference standard. Results Primary tumors showed similar average SUVmax between early (17.89) and delayed scans (17.86, P = 0.241). However, the tumor-to-background ratios of delayed imaging were all significantly higher than those of early imaging (all P < 0.001). In 38 patients who underwent neck dissection, metastatic lymph nodes showed higher mean SUVmax on delayed imaging than on early imaging (early 10.53 ± 5.98 vs delayed 11.71 ± 6.36, P < 0.001), whereas nonmetastatic lymph nodes showed the opposite result (early 3.51 ± 0.51 vs delayed 2.58 ± 0.63, P = 0.002). The mean ∆SUVmax and retention index of metastatic and nonmetastatic lymph nodes were 1.19 versus −0.93 and 12.79% versus −26.55%, respectively. N staging was correctly altered in 3 (3/38) patients based on delayed images. Conclusions Delayed 68Ga-FAPI-04 PET/CT can effectively acquire high-contrast images, better tumor delineation, and detect hidden lesions near or within the tissues influenced by physiological uptake for HNSCC. In addition, dual-time point imaging adds diagnostic value for the differentiation of metastatic from nonmetastatic lymph nodes.

show abstract

Fibroblast Activation Protein Inhibitor PET Imaging in Head and Neck Cancer

Cited by 2 publications

References 23 publications

Diagnostic Accuracy of [68Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis

Diagnostic Accuracy of [68Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis

Dual-Time Point 68Ga-FAPI-04 PET/CT Improves Tumor Delineation and Cervical Lymph Node Metastasis Identification in Patients With Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About